|
시장보고서
상품코드
2102198
원발성 담관염 치료제 시장 규모, 점유율, 성장 분석 : 약물 계열별, 치료 단계별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Primary Biliary Cholangitis Therapeutics Market Size, Share, and Growth Analysis, By Drug Class, By Treatment Line, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 원발성 담관염 치료제 시장 규모는 2024년에 11억 2,000만 달러로 평가되었으며, 2025년 11억 8,000만 달러에서 2033년까지 17억 8,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 5.25%로 성장할 것으로 전망됩니다.
원발성 담관염 치료제 세계 시장은 주로 북미와 유럽을 중심으로, 고령화에 따른 자가면역성 간 질환 유병률 증가에 힘입어 견조한 성장을 이루고 있습니다. 항미토콘드리아 항체 검사나 엘라스토그래피 등의 진단 능력 향상으로 인해 질환의 조기 발견이 가능해지면서, 질환 수정 치료에 대한 수요가 증가하고 있습니다. 우르소데옥시콜산이 기존 치료법으로 사용되어 왔으나, 오베티콜산이나 신규 면역조절제와 같은 새로운 치료법의 등장으로 장기적인 간 보호 전략으로의 전환이 진행되고 있습니다. 섬유화를 역전시키는 2차 치료제의 승인으로 인해, 의료 현장에서는 새로운 치료 요법의 도입이 진행되고 있으며, 일부 지역에서는 이식 의뢰 건수가 대폭 감소한 것으로 확인되었습니다. 이러한 유망한 시장 상황에 힘입어 혁신적인 치료법에 대한 임상시험에 막대한 투자가 유입되고 있으며, 시장은 현저한 성장 궤도에 오를 것으로 예측됩니다.
세계 원발성 담관염 치료제 시장의 성장요인
세계 원발성 담관염 치료제 시장의 성장은 주로 일반 대중과 의료 종사자 모두에게서 이 질환의 초기 증상에 대한 인식이 높아지고 있는 데 기인하며, 이로 인해 신속한 의학적 평가와 조기 치료 시작이 촉진되고 있습니다. 조기 진단은 질병 진행 위험을 줄일 뿐만 아니라 환자의 삶의 질(QOL)을 향상시키고, 나아가 혁신적인 치료법의 적용 대상 환자층을 확대하는 데 기여합니다. 의료 종사자들은 선별 검사의 중요성을 점점 더 강조하고 있으며, 환자 지원 단체들도 인식 제고 자료 제공에 적극적으로 나서고 있습니다. 이러한 추세는 표적화된 임상 이니셔티브와 지속적인 자금 조달 노력에 힘입어, 기존 및 개발 중인 치료법에 대한 수요를 자극하고 있습니다.
세계 원발성 담관염 치료제 시장의 제약요인
세계 원발성 담관염 치료제 시장은 새로 승인된 의약품의 터무니없이 높은 가격 책정으로 인해 큰 과제에 직면해 있습니다. 이는 주로 막대한 연구개발 비용, 복잡한 제조 공정, 그리고 경쟁 부족에 기인하며, 이러한 요인들이 복합적으로 작용하여 환자의 부담을 가중시키고 의료 보험사의 보험금 지급 절차를 어렵게 만들고 있습니다. 예산이 제한된 의료 현장에서는 임상의들이 더 저렴한 기존 치료법에 의존하는 경우가 많아, 혁신적인 치료법의 도입을 저해하고 있습니다. 그 결과, 이러한 상황은 첨단 치료법의 시장 진입을 지연시킬 뿐만 아니라, 제약사가 보험 적용 목록에 등재되는 것을 확보하는 데에도 장애물이 되어 전 세계 공공 및 민간 부문 모두에서 잠재적인 시장 성장을 제한하고 있습니다.
세계 원발성 담관염 치료제 시장 동향
세계 원발성 담관염 치료제 시장에서는 이 질환의 자가면역적 근본 원인을 해결하는 표적형 면역조절제 개발에 중점을 둔 정밀 면역요법의 뚜렷한 동향이 나타나고 있습니다. 이러한 변화는 B세포의 활성이나 사이토카인 경로를 조절하는 치료제에 대한 관심이 높아지고 있음을 특징으로 하며, 단순한 증상 관리에 그치지 않고 보다 효과적인 치료 솔루션을 제공하는 것을 목표로 하고 있습니다. 생명공학 기업, 학술 기관, 환자 지원 단체 간의 공동 연구가 점점 더 활발해지고 있어, 혁신적인 치료 기전의 신속한 도입이 촉진되고 있습니다. 이러한 역동적인 환경 덕분에 기존 치료법으로는 충분한 효과를 얻지 못했던 환자들에게 치료 선택지가 확대되고 있으며, 궁극적으로 이 틈새 시장에서 환자의 예후가 개선되는 결과로 이어지고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 원발성 담관염 치료제 시장 규모 : 약물 계열별
세계의 원발성 담관염 치료제 시장 규모 : 치료 단계별
세계의 원발성 담관염 치료제 시장 규모 : 투여 경로별
세계의 원발성 담관염 치료제 시장 규모 : 유통 채널별
세계의 원발성 담관염 치료제 시장 규모 : 최종사용자별
세계의 원발성 담관염 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.05Global Primary Biliary Cholangitis Therapeutics Market size was valued at USD 1.12 Billion in 2024 and is poised to grow from USD 1.18 Billion in 2025 to USD 1.78 Billion by 2033, growing at a CAGR of 5.25% during the forecast period (2026-2033).
The global market for primary biliary cholangitis therapeutics is experiencing robust growth, largely fueled by an increasing prevalence of autoimmune liver diseases among the aging population, particularly in North America and Europe. Enhanced diagnostic capabilities, such as anti-mitochondrial antibody testing and elastography, have led to earlier disease identification, amplifying the demand for disease-modifying treatments. While ursodeoxycholic acid has been a traditional treatment, emerging therapies like obeticholic acid and novel immunomodulators signal a shift toward long-term liver protection strategies. The approval of second-line agents that reverse fibrosis encourages healthcare systems to adopt new regimens, with significant reductions in transplant referrals noted in certain regions. This promising landscape is attracting substantial investments in innovative therapeutic trials, forecasting a notable market growth trajectory.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Primary Biliary Cholangitis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Primary Biliary Cholangitis Therapeutics Market Segments Analysis
Global primary biliary cholangitis therapeutics market is segmented by drug class, treatment line, route of administration, distribution channel, end user and region. Based on drug class, the market is segmented into bile acid therapies, PPAR agonists, FXR agonists, immunosuppressants, symptomatic therapies and others. Based on treatment line, the market is segmented into first-line therapy, second-line therapy and third-line & salvage therapy. Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics and ambulatory care centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Primary Biliary Cholangitis Therapeutics Market
The growth of the Global Primary Biliary Cholangitis Therapeutics market is largely driven by a heightened awareness among both the public and healthcare professionals regarding the initial symptoms of this condition, promoting prompt medical assessment and faster commencement of treatment options. Diagnosing the disease at an early stage not only lowers the likelihood of its progression but also enhances patients' quality of life, thereby increasing the potential candidate pool for innovative therapies. Medical practitioners are increasingly emphasizing screening practices, while patient advocacy groups are actively sharing educational materials. This trend stimulates demand for both existing and developing treatments, supported by targeted clinical initiatives and ongoing funding efforts.
Restraints in the Global Primary Biliary Cholangitis Therapeutics Market
The Global Primary Biliary Cholangitis Therapeutics market faces significant challenges due to the exorbitant pricing of newly approved medications. This is primarily attributed to extensive research and development expenses, intricate manufacturing processes, and limited competition, which collectively drive up costs for patients and complicate reimbursement efforts for healthcare payers. In healthcare environments with constrained budgets, clinicians often resort to more affordable existing treatments, impeding the adoption of innovative therapies. Consequently, this situation not only delays market entry for these advancements but also creates obstacles for manufacturers in securing formulary access, thereby restricting potential market growth across both public and private sectors worldwide.
Market Trends of the Global Primary Biliary Cholangitis Therapeutics Market
The Global Primary Biliary Cholangitis Therapeutics market is witnessing a notable trend towards precision immunotherapy, emphasizing the development of targeted immunomodulatory agents that address the disease's autoimmune underpinnings. This shift is characterized by a growing focus on therapeutics that modulate B-cell activity and cytokine pathways, thereby aiming to provide more effective treatment solutions rather than merely managing symptoms. Collaborative efforts between biotech firms, academic institutions, and patient advocacy organizations are increasingly prevalent, facilitating quicker adoption of innovative therapeutic mechanisms. This dynamic environment is expanding treatment options for patients with historically inadequate responses to conventional therapies, ultimately enhancing patient outcomes within this niche market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Primary Biliary Cholangitis Therapeutics Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Bile Acid Therapies
- PPAR Agonists
- FXR Agonists
- Immunosuppressants
- Symptomatic Therapies
- Others
Global Primary Biliary Cholangitis Therapeutics Market Size by Treatment Line & CAGR (2026-2033)
- Market Overview
- First-Line Therapy
- Second-Line Therapy
- Third-Line & Salvage Therapy
Global Primary Biliary Cholangitis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
Global Primary Biliary Cholangitis Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Primary Biliary Cholangitis Therapeutics Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Ambulatory Care Centers
Global Primary Biliary Cholangitis Therapeutics Market Size & CAGR (2026-2033)
- North America (Drug Class, Treatment Line, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Drug Class, Treatment Line, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Treatment Line, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Treatment Line, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Treatment Line, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Gilead Sciences Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intercept Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mirum Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genfit SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Calliditas Therapeutics AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- HighTide Therapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr Reddy's Laboratories Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
